PNPLA2 and neutral lipid storage myopathy: Further evidence for the importance of ATGL in LD degradation comes from identification of C-terminal truncation mutations in human ATGL found in patients with a form of Neutral Lipid Storage Disease with Myopathy (NLSDM) [21]–[25].